UK-based Lantern Pharma, which uses artificial intelligence to develop drugs other companies had shelved, has joined Genomic England’s Genomes Project, which is broadening its commercial partnerships to help drive new drug discoveries and developments. Around 40 companies, including pharmaceutical firms, have already signed up to the Genomes Project’s Discovery Forum, which says it aims to develop ground-breaking research into new treatment. Lantern Pharma develops existing cancer drugs which other developers have shelved and uses new techniques to find potential patients through a system called its Response Algorithm for Drug Rescue and Positioning, or RADR.
Texas-based Lantern Pharma, which uses artificial intelligence to develop drugs other companies had shelved, has joined Genomic England’s Genomes Project, which is broadening its commercial partnerships to help drive new drug discoveries and developments. Around 40 companies, including pharmaceutical firms, have already signed up to the Genomes Project’s Discovery Forum, which says it aims to develop ground-breaking research into new treatment. Lantern Pharma develops existing cancer drugs which other developers have shelved and uses new techniques to find potential patients through a system called its Response Algorithm for Drug Rescue and Positioning, or RADR.